乳腺癌易感基因复合蛋白4抗体

参考价:¥1
供货周期: 一周
品牌: Abcam
规格: 0.1ml/100μg
货号:
CAS号:
上海基免实业有限公司
银牌会员4年生产商
关注展位 全部试剂
产品详情

乳腺癌易感基因复合蛋白4抗体英文名称  Anti-BRCC4/BRCC45 
中文名称  乳腺癌易感基因复合蛋白4抗体 
别    名  Brain and reproductive organ expressed (TNFRSF1A modulator); BRCA1/BRCA2 containing complex subunit 4; BRCA1/BRCA2 containing complex subunit 45; BRCC4; BRCC45; BRE_HUMAN. 
浓    度  1mg/1ml 
规 格  0.2ml/200μg   
公司专售乳腺癌易感基因复合蛋白4抗体、肿瘤抑制/凋亡抗体、信号分子抗体、结构蛋白抗体、磷酸化特异抗体、融合蛋白tag抗体、非哺乳动物蛋白抗体、细胞周期蛋白抗体、转录调节蛋白抗体、类固醇受体抗体、膜受体抗体、亚细胞标记抗体、同源结构域蛋白抗体、运输蛋白抗体、生长因子和激素抗体、神经生物抗体、激酶和磷酸化抗体、GDP/GTP结合蛋白抗体、合成降解蛋白抗体、离子通道抗体、淋巴细胞信号抗体、细胞粘附因子抗体、流式抗体等抗体种类,价格合理,品质有保障!      
抗体来源  Rabbit  
克隆类型  polyclonal 
交叉反应  Human, Mouse, Rat, Chicken, Dog, Horse, Rabbit, Sheep   
产品类型  一抗    
研究领域  肿瘤 免疫学 细胞凋亡 细胞周期蛋白  
蛋白分子量  predicted molecular weight: 47kDa 
性    状  Lyophilized or Liquid 
免 疫 原  KLH conjugated synthetic peptide derived from human BRCC4/BRCC45 
亚    型  IgG 
纯化方法  affinity purified by Protein A 
储 存 液  0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide 
产品应用   WB=1:100-500  ELISA=1:500-1000  IP=1:20-100  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500 
(石蜡切片需做抗原修复) 
 not yet tested in other applications.
 optimal dilutions/concentrations should be determined by the end user.  
保存条件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 
Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 
乳腺癌易感基因复合蛋白4抗体产品介绍 BRCC45 was initially suggested to be a housekeeping protein that is highly expressed in brain and reproductive organs. Later experiments indicated BRCC45 forms a complex with the breast and ovarian predisposition proteins BRCA1 and BRCA2 as well as RAD51 and BRCC36. This complex has a ubiquitin E3 ligase activity and is thought to enhance cellular survival following DNA damage. BRCC45 has also been suggested to function as a death receptor associated anti apoptotic protein by inhibiting the BID induced activation of the mitochondrial apoptotic pathway. Higher levels of BRCC45 were detected in the majority of hepatocellular carcinomas, suggesting that BRCC45 may promote tumorigenesis when overexpressed. At least three isoforms of BRCC45 are known to exist.
Function : Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX. In the BRCA1-A complex, it acts as an adapter that bridges the interaction between BABAM1/NBA1 and the rest of the complex, thereby being required for the complex integrity and modulating the E3 ubiquitin ligase activity of the BRCA1-BARD1 heterodimer. Probably also plays a role as a component of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin. May play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. May also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway. May regulate TNF-alpha signaling through its interactions with TNFRSF1A; however these effects may be indirect. 
Subunit : Component of the BRCA1-A complex, at least composed of the BRCA1, BARD1, UIMC1/RAP80, FAM175A/Abraxas, BRCC3/BRCC36, BRE/BRCC45 and BABAM1/NBA1. In the BRCA1-A complex, interacts directly with FAM175A/Abraxas, BRCC3/BRCC36 and BABAM1/NBA1. Binds polyubiquitin. Component of the BRISC complex, at least composed of the FAM175B/ABRO1, BRCC3/BRCC36, BRE/BRCC45 and BABAM1/NBA1. Component of the BRCA1/BRCA2 containing complex (BRCC), which also contains BRCA1, BRCA2, BARD1, BRCC3/BRCC36 and RAD51. BRCC is a ubiquitin E3 ligase complex that enhances cellular survival following DNA damage. May interact with FAS and TNFRSF1A.
Subcellular Location : Cytoplasm. Nucleus. Note=Localizes at sites of DNA damage at double-strand breaks (DSBs). 
Tissue Specificity : Expressed in all cell lines examined. Highly expressed in placenta.
Similarity : Belongs to the BRE family.
Database links : UniProtKB/Swiss-Prot: Q9NXR7.2
在纯化抗体时需要控制好几个指标,包括纯度、含量及抗体的抗原结合活性。
纯度:在实验的任何阶段,确定抗体溶液纯度的最简单方法是取一部分样本进行SDS-PAGE电泳。凝胶可用考马斯亮蓝染色(灵敏度为0.1—0.5ug/带)或银染(灵敏度1~l0ug/带)。 
定量:如果抗体还不纯,有一个快捷的定量方法,即通过SDS-PAGE电泳分离出轻、重链,然后和已知的标准染色带比较。如果需要分析许多样本,用免疫测定法对抗体定量较容易。如果抗体是经过纯化的,可通过测蛋白总量代替上述两种方法,有一简单的方法,即紫外吸收法。乳腺癌易感基因复合蛋白4抗体的量可通过测280nm处的吸收值来测(10D大致相当于0.75mg/m1的纯化抗体)。
抗原结合活性:一般说来,纯化方法不会引起抗原结合活性的改变。用蛋白G或蛋白A树脂很少导致抗体活性丧失。然而,如果最终抗体产物的作用不如原来所预料的好,检测抗体纯化过程所丢失的活性就极为重要。用一系列滴定法比较纯化的抗体和其原材料的活性,以标定每一步中的总抗体量,这将有助于较好的估计通过纯化所丢失的活性。

相关产品

同类推荐 更多
乳腺癌易感基因复合蛋白4抗体由上海基免实业有限公司为您提供,货号,规格:0.1ml/100μg,CAS号:,如您想了解更多关于乳腺癌易感基因复合蛋白4抗体价格、乳腺癌易感基因复合蛋白4抗体结构式、批发、用途等信息,欢迎咨询。除供应乳腺癌易感基因复合蛋白4抗体外,还可为您提供其他等试剂,公司有专业的客户服务团队,是您值得信赖的合作伙伴,上海基免客户服务电话,售前、售后均可联系。
Business information
工商信息 信息已认证
contact us
联系方式

详细地址

上海市金山工业区亭卫公路6558号9幢2441室
当前位置: 上海基免 试剂 乳腺癌易感基因复合蛋白4抗体

关注

拨打电话

留言咨询